Close Menu

NEW YORK (360Dx) – T2 Biosystems announced today that it has closed its previously announced public offering, raising about $52.6 million in gross proceeds.

The firm sold about 7 million shares of its common stock, including 915,000 shares to the offering's underwriters, who exercised in full their option to purchase additional shares at a price of $7.50 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.